MARKETS / COMPANIES / ECONOMYRSS edition ↗
Capital Beacon
Healthcare Stocks

FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claims

Benchmarks Nifty22,965.80343.1FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.52 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.82 % Invest NowEnter search…

FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claims
Benchmarks Nifty22,965.80343.1FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.52 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return18.82 % Invest NowEnter search text:
    The Economic Times daily newspaper is available online now. Read Today's Paper FSSAI pulls up Dr Reddy's, Nestle Health Science over Celevida claimsBy ET BureauLast Updated: Oct 09, 2026, 12:34:00 AM ISTSynopsis

    The Food Safety and Standards Authority of India (FSSAI) said the product was advertised as providing high-protein support for preserving lean muscle during GLP-1/GIP therapies, commonly used in weight-loss treatment.

    Listen to this article in summarized format

    Loading...×New Delhi: Food safety regulator FSSAI has issued notices to Dr Reddy's and Nestle Health Science, Flipkart, Amazon and three other entities over allegedly misleading advertising and health claims for Celevida GLP+, a nutrition product marketed on ecommerce platforms.

    The Food Safety and Standards Authority of India (FSSAI) said the product was advertised as providing high-protein support for preserving lean muscle during GLP-1/GIP therapies, commonly used in weight-loss treatment.

    FSSAI said claims such as 'helps maintain lean muscle', 'support muscle strength' and 'preserve lean mass' suggested the product could help prevent muscle loss during weight reduction and GLP-1/GIP therapy.

    Also read | Dr Reddy’s Laboratories receives two observations for Andhra Pradesh facility

    FSSAI also found that the brand name 'Celevida GLP+', together with the promotional claims, created a misleading association with these therapies. It said a disclaimer clarifying that GLP+ was only a brand name was insufficient to address the overall impression.

    Live Events


        The regulator also questioned claims describing the product as 'complete daily nourishment' and 'dependable nutrition in every serving', saying these could suggest it was a complete nutrition product or meal replacement. Other claims flagged included 'Imported from Europe for purity' and 'Contains 100% RDA BCAA'. FSSAI said European origin did not establish superior purity while BCAA claim was ambiguous and misleading.

        Also read | I-T dept moves appellate tribunal against Rs 32.66-cr tax relief to Dr Lal PathLabs

        FSSAI has directed the food businesses to discontinue use of term '100%' on food labels, packaging and promotional material. It has also asked them to show cause why action should not be initiated under the Food Safety and Standards Act, 2006, and the relevant regulations.
        Add as a Reliable and Trusted News Source Add Now!
        (You can now subscribe to our Economic Times WhatsApp channel)
        Read More News onFSSAIDr Reddy'sCelevida GLP+celevidadr reddy's fssai case

        (Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

        ...moreless
        (You can now subscribe to our Economic Times WhatsApp channel)
        Read More News onFSSAIDr Reddy'sCelevida GLP+celevidadr reddy's fssai case

        (Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

        ...morelessContinue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories
        & personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
        in-depth stock reportsSubscribe NowET

        Unlock Access to All Exclusives with ETPrime FREE TRIAL

        15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

        Trial offer expiring in00 : 05 : 00

        I'd rather pay ₹2599 now

        Uh-oh! This is an exclusive story available for selected readers only.

        Worry not. You’re just a step away.

        Prime Account Detected!

        It seems like you're already an ETPrime member with

        Login using your ET Prime credentials to enjoy all member benefits

        Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

        Unlock ETPrime's Exclusive Stories Today!

        Big Price Drop! Flat 40% Off

        Student Only OfferAlready a Member? Sign In nowAlready a Member? Sign In nowAlready a Member? Sign In now

        Offer Exclusively For You

        Save up to Rs. 700/-

        ON ET PRIME MEMBERSHIP

        Avail Offer

        Offer Exclusively For You

        Get 1 Year Free

        With 1 and 2-Year ET prime membership

        Avail Offer

        Offer Exclusively For You

        Get 1 Year Free

        With 1 and 2-Year ET prime membership

        Avail Offer

        Offer Exclusively For You

        Get Flat 40% Off

        Then ₹ 1749 for 1 year

        Avail Offer

        Offer Exclusively For You

        ET Prime at ₹ 49 for 1 month

        Then ₹ 1749 for 1 year

        Avail Offer

        Special Offer

        Get flat 40% off on ETPrime

        Avail OfferAvail OfferClaim NowAlready a Member? Sign In now

        Need Assistance?

        Connect with an ETPrime expert for personalized support and guidance

        +91 9484700004'; }); } if(listing) { var h3 = "You tried reading " + listArr.length + " locked stories in the past " + threshold + " days.", h4 = "Become an ET Prime member and don't miss out on these exclusive stories."; var html = '

        ' + h3 + '

        ' + h4 + '

          ' + listing + '
        '; $('#paidSCWidget').html(html); var callback = $('#paidSCWidget').attr('data-callback'); if(callback && window[callback]) { window[callback](); } customDimension.dimension72 += ' | Shown SYFT no Trial_With Missed Paywalled Articles Collection'; } else { _processNormal() } } }); } else { _processNormal(); } } catch (e) { _processNormal(); } }, function () { _processNormal(); }); //console.log('storyCollectionLoad', $); }

        What’s Included with

        ETPrime Membership

        1Exclusive Insights That Matter

        Uncover the truth with our investigative stories

        Make strategic moves using the real-world case studies

        Read industry-specific stories to identify emerging trends

        Spot opportunities with
in-depth insights that matter

        • Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

          What Adani’s US indictment means for India Inc’s overseas fundraising

        • Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

          Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?

        • Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

          The problem with lab grown diamonds

        • Why a falling rupee is a better option for the economy

          A list of top 20 momentum stocks that have delivered massive returns in one year

          2Invest Wisely With Smart Market Tools & Investment Ideas

          Alpha Trade

          Get daily trade ideas from SEBI-registered research analysts.

          Investment Ideas

          Grow your wealth with stock ideas & sectoral trends.

          Stock Reports Plus

          All-in-one stock research with Stock Score, peer comparison & key signals.

          BigBull Portfolio

          Get to know where the market bulls are investing to identify the right stocks.

          Stock Analyzer

          Check the score based on the company's fundamentals, solvency, growth, risk & ownership to decide the right stocks.

          Market Mood

          Analyze the market sentiments & identify the trend reversal for strategic decisions.

          Stock Talk Live at 9 AM Daily

          Ask your stock queries & get assured replies by ET appointed, SEBI registered experts.

          3Stay informed anytime, anywhere with ET ePaper

          ePaper - Print View

          Read the PDF version of ET newspaper. Download & access it offline anytime.

          ePaper - Digital View

          Read your daily newspaper in Digital View & get it delivered to your inbox everyday.

          Wealth Edition

          Manage your money efficiently with this weekly money management guide.

          TOI ePaper

          Read the PDF version of TOI newspaper. Download & access it offline anytime.

          Deep Explainers

          Explore the In-depth explanation of complex topics for everyday life decisions.

          Health+ Stories

          Get fitter with daily health insights committed to your well-being.

          Personal Finance+ Stories

          Manage your wealth better with in-depth insights & updates on finance.

          5Enjoy Complimentary Subscriptions From Top Brands

          Stream new documentaries from all across the world every day.

          Stories you might be interested in

            Source: Economic Times — Healthcare/Biotech ↗

            Figures reflect the source report and its stated period. This article is for information and is not investment advice.